← Back to Search

NMDA Receptor Antagonist

Ketamine + Cognitive Training for Suicidal Behavior

Phase 4
Waitlist Available
Led By Rebecca B Price, PhD
Research Sponsored by Rebecca Price
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants who receive ketamine will: be between the ages of 18 and 65 years
be deemed an appropriate and reasonable medical candidate for intravenous ketamine by a physician authorized to prescribe medication to the patient during inpatient hospitalization
Timeline
Screening 3 weeks
Treatment Varies
Follow Up trajectories from 24hrs through 12 months
Awards & highlights

Study Summary

This trial will test whether ketamine can help suicidal patients in the short and long term, and whether a computer training protocol can extend ketamine's effects.

Who is the study for?
This trial is for adults aged 18-65 who are hospitalized, experiencing suicidality, and need psychiatric hospitalization. They must be able to consent and not have a history of severe reactions to ketamine or certain mental conditions like acute psychosis or developmental disorders with significant impairments.Check my eligibility
What is being tested?
The study tests if a single dose of intravenous ketamine can reduce suicidal thoughts quickly. It also examines whether combining this treatment with computer-based cognitive training can extend its benefits.See study design
What are the potential side effects?
Ketamine may cause side effects such as disorientation, dizziness, nausea, increased blood pressure, mood swings, blurred vision, and in rare cases dissociation or hallucinations.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 65 years old.
Select...
My doctor agrees I am a good candidate for ketamine treatment in the hospital.
Select...
I understand the study requirements and have signed the consent form.
Select...
I was referred for a psychiatric evaluation due to feeling suicidal and need to be hospitalized.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~trajectories from 24hrs through 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and trajectories from 24hrs through 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Suicidal behaviors: medical chart review and Columbia Suicide Severity Rating Scale (CSSRS)
Secondary outcome measures
Adult Suicide Ideation Questionnaire
Montgomery Asberg Depression Rating Scale
Quick Inventory of Depressive Symptoms
+1 more
Other outcome measures
Acceptability: infusion
Ease of use: Cognitive Training
Future likelihood of use: Cognitive Training
+5 more

Side effects data

From 2022 Phase 1 & 2 trial • 154 Patients • NCT03237286
22%
dissociative effects
20%
dizziness
14%
nausea
10%
dry mouth
8%
difficulty sleeping: too much
8%
headache
6%
sweating
6%
decreased energy
4%
restlessness
4%
anxiety
4%
elevated blood pressure
2%
tremors
2%
difficulty sleeping: too little
2%
emotional indifference
2%
increased appetite
100%
80%
60%
40%
20%
0%
Study treatment Arm
Saline
Ketamine

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Ketamine + Cognitive TrainingExperimental Treatment2 Interventions
Group II: No-infusion (TAU) + Cognitive TrainingActive Control1 Intervention
Group III: Ketamine + Sham TrainingPlacebo Group2 Interventions
Group IV: No-infusion (TAU) + Sham TrainingPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cognitive training
2019
Completed Phase 3
~1480
Ketamine
FDA approved

Find a Location

Who is running the clinical trial?

Rebecca PriceLead Sponsor
6 Previous Clinical Trials
468 Total Patients Enrolled
National Institute of Mental Health (NIMH)NIH
2,774 Previous Clinical Trials
2,674,103 Total Patients Enrolled
5 Trials studying Suicide Attempt
28,921 Patients Enrolled for Suicide Attempt
Rebecca B Price, PhDPrincipal InvestigatorUniversity of Pittsburgh
1 Previous Clinical Trials
200 Total Patients Enrolled

Media Library

Intravenous ketamine (NMDA Receptor Antagonist) Clinical Trial Eligibility Overview. Trial Name: NCT04578938 — Phase 4
Suicide Attempt Research Study Groups: Ketamine + Cognitive Training, Ketamine + Sham Training, No-infusion (TAU) + Cognitive Training, No-infusion (TAU) + Sham Training
Suicide Attempt Clinical Trial 2023: Intravenous ketamine Highlights & Side Effects. Trial Name: NCT04578938 — Phase 4
Intravenous ketamine (NMDA Receptor Antagonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04578938 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this medical research accept volunteers aged 80 or older?

"Participants must be between 18 and 65 years of age to qualify for this medical trial."

Answered by AI

To what extent can IV ketamine be detrimental to one's health?

"Based on its status as a Phase 4 trial, which is the final step before clinical approval, ketamine was assigned a safety rating of 3."

Answered by AI

What is the primary goal of this research?

"This trial will monitor and measure suicidal behaviour, depression severity, and self-reported depression over the course of a year. Indicators include Adult Suicide Ideation Questionnaire (range: 0-150; high score=worse outcome), Montgomery Asberg Depression Rating Scale (range 0-60; high score=worse outcome) and Quick Inventory of Depressive Symptoms (range: 0-27; higher scores = worse outcome)."

Answered by AI

Are there any openings to join this medical trial?

"Based on information published to clinicaltrials.gov, this experiment is no longer recruiting participants. The trial was first posted in March 2021 and last edited in November 2022. Despite the conclusion of recruitment for this particular study, there are still 273 other studies that require applicants at present."

Answered by AI

Am I eligible to participate in this research trial?

"This clinical trial is recruiting 200 participants aged 18 to 65 who have attempted parasuicide. In order for a patient to qualify, they must possess the capacity to sign an informed consent document, be referred by C/L psychiatry and deemed medically suitable for intravenous ketamine treatment as judged by an authorised physician."

Answered by AI

How many individuals have been recruited for participation in this investigation?

"At present, this clinical trial is not enrolling any new patients. The initial posting was on March 15th 2021 and the latest update occurred November 22nd 2022. If you are seeking other research opportunities, there are 168 trials for parasuicide recruiting participants and 105 studies involving Intravenous ketamine that require volunteers."

Answered by AI

Who else is applying?

What portion of applicants met pre-screening criteria?
Did not meet criteria
~78 spots leftby Mar 2026